BEIJING, March 26, 2026 /PRNewswire/ — A news report from chinadaily.com.cn:
Join China Daily journalist Erik Nilsson on a tour of Beijing to explore its timeless charm alongside a tech-powered future. A stroll around Beijing is a journey through time, where centuries-old heritage coexists with cutting-edge innovation. The Beijing Central Axis reveals the city’s historical heart. At the Choc Choco Chocolate Museum, history takes the form of edible art. In Beijing E-Town, visitors experience the forefront of artificial intelligence, while the ancient Grand Canal continues to breathe new life into urbanization.
Equipped with DJI’s flagship 1-inch imaging, O4+ video transmission, and omnidirectional obstacle sensing, creators can now film 360 footage in 8K with ease
SHENZHEN, China, March 26, 2026 /PRNewswire/ — DJI, the global leader in civilian drones and creative camera technology, today launches Avata 360. Designed to unlock endless creativity in one take[1], DJI’s new 8K 360° flagship drone delivers 360° imaging with 1-inch-equivalent sensors[1] for filming in 8K/60fps HDR video. Meanwhile, DJI’s powerful O4+ video transmission system and obstacle sensing[1] enable creators to see farther with a more stable, safer, and more immersive flight experience. Paired with DJI goggles and motion controllers, the latest addition to the popular Avata series delivers an immersive 360° flight experience for FPV thrills. Creators can also use DJI remote controllers to capture a full 360° view in a single flight that can be reframed from any perspective, transforming a single take into multiple creative possibilities.
DJI Avata 360 Sets New Standards for Immersive 360 FPV Flying
Brilliant Imaging, Boundless Creativity
Avata 360 offers two different lenses that can be seamlessly switched. The 360° lens uses 1-inch-equivalent sensors[1] that can capture 360° images in rich detail for 8K/60fps HDR videos[1] and 120 MP photos. With the large 2.4 μm pixels and high dynamic range, light and shadow are also captured with exquisite clarity. Both video and photos can be exported directly or reframed in post-production. Meanwhile, the Single Lens mode allows creators to use the classic Avata-style filming in 4K/60fps[1].
Powerful Video Transmission, Immersive Flight
Avata 360 leverages DJI’s flagship O4+ video transmission system to deliver stable and clear live feeds for smoother, more immersive flights. Its strong anti-interference capabilities enable high-definition, high-frame-rate transmission at 1080p/60fps and support a range of up to 20 km[1].
Fly With Confidence, Create With Ease
Avata 360 offers up to 23 minutes of flight time[1] and includes several standard safety features, including nightscape omnidirectional obstacle sensing[1] and integrated propeller guards. If damaged, the camera lens can be easily replaced with the DJI Avata 360 replacement lens kit with tools (sold separately). It also brings an exceptional experience to aerial content creation, where a single shot with the drone’s 360° imaging can be transformed into multiple, masterful creations through post production using the DJI Fly and DJI Studio apps, including:
Spotlight Free[1] – Locks onto a moving subject and assists with camera movement, replicating the sophisticated camera language like a pro with Inspire 3. By comparison, Spotlight locks onto your subject’s face to effortlessly capture Circle or Dronie shots without manual adjustments.
ActiveTrack 360°[1] – Automatically selects the optimal tracking mode. For example, Standard mode maintains a steady distance and altitude relative to the subject. Meanwhile, Cycling mode reacts faster to turns and keeps the subject in frame even in complex environments.
FPV mode – Enables even novice pilots to adds a natural roll effect to Spotlight Free, ActiveTrack 360°, and manual flights to create dynamic, high-speed FPV-style footage. This mode can be applied in post-production.
Intelligent Tracking – Powered by advanced algorithms, DJI Fly and DJI Studio apps make it effortless to lock onto and smoothly track people, vehicles, pets, and more, even in 360° footage.
New One-Tap In-App Editing – With GyroFrame, 360° footage can be adjusted to an ideal angle and exported in the DJI Fly app. Both DJI Fly and DJI Studio allow camera movement effects to be added.
Virtual Gimbal[1] – Uses a 360° view to enable infinite rotation and tilt for dynamic camera moves. Even when flying in one direction, horizons can be rotated, and perspectives can be shifted to look back or perform a flip.
Replaceable Front Lens Element – The front element features a replaceable design. Purchase a replacement lens kit with tools[1], and you can easily replace the old lens yourself—no need to send it in for repair.
42GB Internal Storage and High-Speed Transfers – With 42GB of internal storage, 30 minutes of 360° video in 8K without a microSD card. Using Wi-Fi 6 High-Speed Transfer, 1 GB of footage can be transferred to the DJI Fly app in 10 seconds at up to 100 MB/s[1].
FPV Flights and Aerial Filming in One Drone
Avata 360 combines the creative freedom of a 360 camera with the thrill of FPV flying like never before. It can be flown with DJI remote controllers (RC 2, RC-N2, RC-N3) for precise camera movement, allowing creators to unlock new ways to create stunning aerial shots. Meanwhile, DJI goggles and motion controllers offer a more immersive flight experience with 360° imaging at 1080p/60fps. Like the Avata 2, aerial acrobatics like drifting can be performed – even by beginners – with the DJI RC Motion 3.
Price and Availability
DJI Avata 360 is available for pre-order starting today through store.dji.com and authorized retailers. Shipping begins April 2026 and will vary by region. Pricing and configurations are as follows:
DJI Avata 360 (Drone Only) retails for £409.
DJI Avata 360 (DJI RC 2) retails for £639.
DJI Avata 360 Fly More Combo (DJI RC 2) retails for £829.
DJI Avata 360 Motion Fly More Combo retails for £829.
DJI Care Refresh
DJI Care Refresh, the comprehensive protection plan for DJI products, is now available for DJI Avata 360. The replacement service covers accidental damage, including flyaway, collisions and water damage. For a small additional charge, you can have your damaged product replaced if an accident occurs.
DJI Care Refresh (1-Year Plan) includes up to two replacements in one year. DJI Care Refresh (2-Year Plan) includes up to four replacements in two years. Other services of DJI Care Refresh include official Warranty and free shipping. For a full list of details, please visit: https://www.dji.com/support/service/djicare-refresh.
[1] Only supported by certain camera modes or with specific accessories. All data was measured using a production model of DJI Avata 360 in a controlled environment; actual experience may vary. For more information, please refer to https://www.dji.com/avata-360.
SUZHOU, China, March 26, 2026 /PRNewswire/ — Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.
During the year, the Group delivered steady revenue growth and continued improvement in operating efficiency, while advancing multiple key pipeline programs. Against a dynamic industry backdrop, the Group’s core business demonstrated increasingly resilience. The Neurointerventional Business emerged as a stronger earnings contributor, while the Transcatheter Valve Therapeutic Business continued to expand its platform, enhance commercialization capabilities and improve its profitability profile.
Steady Growth with Improving Profitability Profile
For the year ended December 31, 2025, the Group recorded total revenue of RMB712.9 million, representing a year-on-year increase of 15.8%. Revenue contribution remained balanced, with TAVR-related products accounting for 40.7% and neurointerventional products accounting for 59.3% of total revenue.
While maintaining a relatively stable gross margin, the Group continued to strengthen cost discipline and improve operating efficiency, supported by scale expansion and more focused resource allocation. Excluding the losses attributable to the entities comprising the Future Technology Business [1], the Group’s adjusted loss for the year narrowed by 44.1% year on year to RMB110.5 million, reflecting a clear trend of improving underlying profitability.
Neurointerventional Business: Profit Contribution Accelerates and Globalization Begins
The Neurointerventional Business continued to deliver strong earnings growth during the year. Segment profit increased by 86.6% year on year to RMB97.2 million, while segment profit margin improved to 23.0%. The significant profit expansion was driven by continued revenue growth, disciplined cost management and improved operating efficiency, indicating that operating leverage is increasingly being realized as the business scales.
The segment also achieved a key milestone in its globalization strategy. In March 2026, DCwire® received 510(k) clearance from the U.S. Food and Drug Administration, marking the Group’s first regulatory approval in the United States. This milestone validates the competitiveness of the Group’s products and establishes a foundation for further expansion into global markets.
TAVR Business: Leadership Reinforced with Expansion into New Indications
The Group maintained its leading position in China’s TAVR market and continued to expand its commercialization footprint. During the year, revenue from TAVR-related products increased by 11.6% year on year to RMB290.1 million. Total implant volume reached approximately 3,900 units, up 14.4% year on year, while the Group’s products were adopted by more than 780 hospitals, including approximately 130 newly added hospitals during the year.
The Group’s Taurus product family continued to gain strong clinical recognition in the treatment of aortic stenosis, supported by a comprehensive portfolio spanning core and premium offerings. At the same time, the approval of TaurusTrio® (the Group’s localized product licensed from the JenaValve TrilogyTM THV System for Greater China) in December 2025 for the treatment of symptomatic, severe aortic regurgitation marked a major strategic milestone. This approval expands the Group’s valve platform from a single-indication focus to a broader multi-indication platform, opening new growth opportunities and strengthening its long-term competitive positioning.
Pipeline Momentum and Multiple Near-Term Catalysts
The Group continued to make steady progress across its pipeline, supporting the next phase of growth. In China, registration applications were submitted for TaurusNXT®, the Group’s next-generation durability-enhanced TAVR product, and GeminiOne®, its transcatheter edge-to-edge repair (TEER) system. Patient enrollment for the registration clinical trial of HighLife®, the Group’s licensed-in trans-septal mitral valve replacement system continued to accelerate, while ReachTact®, the Group’s robotic-assisted TAVR system, entered registration clinical trial phase.
Globally, GeminiOne® has been submitted for EU MDR CE Mark registration, while other pipeline programs continue to advance through clinical development.
As of the end of 2025, seven of the Group’s transcatheter valve therapeutic products had been included in the National Medical Products Administration (NMPA) Innovative Medical Device Special Review Procedure, ranking first in the industry and highlighting the Group’s strong innovation capabilities.
Management Commentary
Dr. Yi Zhang, Chairman and CEO of Peijia Medical, commented:
“2025 was a year of steady progress and strengthening fundamentals for Peijia. Our Transcatheter Valve Therapeutic Business continued to expand its commercialization platform and growth potential, while our Neurointerventional Business delivered accelerated profit growth and is becoming an increasily important contributor to the Group’s earnings.
Looking ahead to 2026, we see both new opportunities and higher expectations. We will remain focused on disciplined execution, continuous innovation and long-term value creation as we advance into the next stage of growth.”
Note:
[1] Future Technology Business, established in 2024 and spun off from the Transcatheter Valve Therapeutic Business, focuses on developing globally leading therapies for valvular heart diseases. It currently includes three pipeline products: the Lithotripsy Valvuloplasty System, MonarQ TTVR® System, and ReachTact® TAVR Assistance System. Each project is operated by dedicated teams and advanced through specialized subsidiaries with operational and financing autonomy.
About the Company
Peijia Medical (9996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has four TAVR systems and near twenty neurointerventional devices commercialized in China and various innovative product candidates at different stage of development. For more information about Peijia visit https://www.peijiamedical.com/.
Reinforcing long-term commitment to embedding sustainability across operations and partnerships
Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide
INCHEON, South Korea, March 26, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), received recognition at the 2026 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect. The company was awarded the Sustainability Leadership Award, a jury-selected distinction recognizing efforts to advance sustainable practices across its operations and value chain. Samsung Biologics was also named “Best in Class” in Cultural Fit in the ‘Biologics—Large CDMOs’ category, reflecting its strong, collaborative partnerships built on shared goals and close alignment with client needs.
The CDMO Leadership Awards recognize top-performing development and manufacturing service providers based on global client feedback across areas such as facilities, innovation, technical expertise, and manufacturing capabilities. Samsung Biologics has been consistently recognized at the CDMO Leadership Awards, supported by strong client feedback on its ability to deliver reliable execution and maintain consistent service quality. In addition, this year’s Jury Awards are determined by an independent panel of industry experts, informed by survey data and broader industry input.
Attending the awards ceremony in New York on the sidelines of DCAT Week, Samsung Biologics said the recognition reflects the company’s ongoing efforts to maintain stable, resilient, and sustainable practices to support client programs.
“Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships,” said John Rim, President and CEO of Samsung Biologics, who also serves as champion for the Sustainable Markets Initiative (SMI) Supply Chains Working Group. “This recognition reflects the trust our clients and partners continue to place in us, as well as the dedication of our teams who consistently strive to integrate sustainable practices across our operations. We will continue to advance these efforts in close collaboration with our partners, supporting their long-term goals and the delivery of high-quality, life-saving medicines to patients worldwide.”
Samsung Biologics also recently achieved a Platinum rating from EcoVadis, awarded to top-performing companies worldwide in sustainability practices. The company has also implemented a product carbon footprint (PCF) system, which has been independently validated to support transparent and consistent emissions measurement. While continuing its role as a Champion of the SMI Health Systems Task Force, Samsung Biologics will further strengthen engagement with global suppliers in decarbonization efforts and the development of more resilient value chains.
About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.
With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 liters from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics continues to expand its manufacturing footprint. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.
Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics
By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.
Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.
Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.
Interline cooperation launched with Star Alliance member Thai Airways
Expands connectivity via Bangkok hub across Southeast Asia and India, targeting transit demand to the Americas
SEOUL, South Korea, March 26, 2026 /PRNewswire/ — Air Premia, Korea’s only hybrid service carrier, announced that it has entered an interline partnership with Thailand’s national flag carrier, Thai Airways, with joint transportation services set to commence on March 30.
Air Premia Expands Americas–Southeast Asia Connectivity Through Interline Partnership with Thai Airways
Through this collaboration, Air Premia aims to capture transit demand from Southeast Asia and India traveling to the Americas via Incheon, while Thai Airways will be able to expand its network into the U.S. market through Air Premia’s long-haul routes from Incheon. Currently, there are no direct flights connecting Thailand and the United States.
Under the agreement, the two airlines will offer joint ticketing. Passengers will benefit from seamless travel across both carriers’ networks with a single booking, enabling convenient access to a wider range of destinations.
Air Premia currently operates long-haul routes from Incheon to major U.S. destinations, including Los Angeles, New York, San Francisco, Honolulu, and Washington, D.C. (planned), as well as regional routes across Asia, including Narita, Bangkok, Da Nang, and Hong Kong.
Thai Airways, the largest full-service carrier in Thailand, operates eight domestic routes and 54 international routes across Asia, Europe, and Oceania from its hub at Bangkok’s Suvarnabhumi Airport. It is also a founding member of the Star Alliance, the world’s largest airline alliance.
Through this interline partnership, Air Premia’s Americas routes will be connected to Thai Airways’ extensive network, including key domestic destinations in Thailand such as Phuket and Chiang Mai, as well as major cities across Southeast Asia—including Kuala Lumpur, Singapore, Jakarta, and Hanoi—and India, including New Delhi, Mumbai, and Chennai.
On the Incheon–Bangkok route, both airlines operate services, with Thai Airways offering three daily flights. This increased frequency is expected to provide greater flexibility and more options for passengers, further supporting the growth of transit demand to the Americas.
“Through this interline partnership with Thai Airways, a Star Alliance member, we expect to expand transit demand from Southeast Asia and India to the Americas,” said an Air Premia official. “We will continue to broaden travel options for our customers by strengthening cooperation with various airline partners.”
“Always with You, Always Ahead,” From banking services to life protection planning, professionally supports your journey with peace of mind
HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Ping An Digital Bank (International) Limited (“Ping An Digital Bank” or “PingAnDB”) unveils its new branding today. As one of the integrated financial platforms in Hong Kong under Ping An Insurance (Group) Company of China, Ltd. (“Ping An”; SEHK: 2318; SSE: 601318), Ping An Digital Bank leverages the Group’s technology integrated strength to embark on an exciting new chapter.
With a core commitment to enhancing customer experience, Ping An Digital Bank adheres to its vision of “Always with You, Always Ahead.” Harnessing innovative technology, the Bank redefines the digital banking journey, making it simpler for customers to manage their deposits, investments, and insurance – all from a single account from their mobile device. Striving to anticipate customer needs and go the extra mile, Ping An Digital Bank empowers customers to take smarter steps towards financial growth and accumulate wealth steadily over time, without the burden of complex procedures or heavy research.
Mr. Ronald Iu, Chief Executive of Ping An Digital Bank, said, “We are delighted to unveil a brand new Ping An Digital Bank. This better reflects our deep connection with Ping An Group, integrating our signature ‘insurance DNA’ directly into our banking services and further reinforcing our role as an integrated financial platform in Hong Kong. Moving forward, Ping An Digital Bank will continue to develop both retail and business banking. Our team is dedicated to our brand vision of ‘Always with You, Always Ahead’ as our brand image transforms – building trust as the foundation, and simplicity as our priority. From banking to life protection planning, our professional team stands ready to support our clients throughout every stage of their financial journey.”
Retail Banking: User-Centric at the Core One Account for Deposits, Investments & Insurance Since joining Lufax in 2024, Ping An Digital Bank has accelerated the development of its retail banking offerings, launching online and offline insurance, as well as wealth services. With one single account that integrates deposits, foreign exchange, cross-border remittances, wealth and insurance, customers can now enjoy truly one-stop financial experience. As of 15 March 2026, total retail banking deposits have surpassed HK$ 12 billion.
With user-friendliness at the heart of its design, Ping An Digital Bank’s retail banking services aim to minimise redundant steps and simplify money management. The latest dual-advantage wealth solution marries the experience of agility of a brokerage with the security of a bank, allowing customers to invest in Hong Kong stocks, U.S. stocks, funds, and money market funds directly from their savings accounts with no extra transfers required, enabling customers to SWITCH flexibly between investment and deposit services.
Powered by Ping An’s robust insurance pedigree, Ping An Digital Bank leads the market as Hong Kong’s first digital bank to provide a full spectrum of online and offline insurance services. For unrivalled efficiency, customers can purchase general insurance products, including motor insurance, travel insurance, and home insurance products, online within minutes. For client-centric experience with human touch, the Bank’s offline platform delivers an extensive range of life protection and savings plans, tailored to each client’s needs.
Business Banking: A Pillar of Support for Trade Enterprises Driving Breakthroughs with Data & Technology As a leading digital bank for SMEs in Hong Kong, Ping An Digital Bank plays a pivotal role in supporting the city’s trading enterprises. By harnessing advanced technology and business data, the Bank is striving to help unleash the full potential of Hong Kong’s digital economy while backing the HKSAR Government’s vision for smart city development. Through the integration of trade, logistics, and financial data, Ping An Digital Bank is revolutionising the credit approval process to deliver quicker and more flexible assessments, empowering a broader range of businesses to seize new opportunities.
From account opening and foreign exchange to cross-border remittances and financing, Ping An Digital Bank stands as a key pillar of support for trading enterprises, providing an integrated business banking suite that meets the practical needs of companies in both daily operations and international expansion. Leveraging innovative data models, the Bank empowers trading SMEs to advance their operations and thrive, and thus becoming a dedicated and trusted partner for business growth.
Looking ahead, Ping An Digital Bank will continue to put customer convenience at the heart of its services, striving to help both individuals and businesses to save time, effort and cost. The Bank is dedicated to setting new benchmarks for digital banking, while reinforcing its position as a key pillar within Ping An Group’s integrated financial platform in Hong Kong.
Investment involves risk. The price of investments fluctuates, sometimes dramatically. The price of investments may move up or down, and may become valueless. There is an inherent risk that losses may be incurred rather than profit made as a result of buying and selling investment products. Foreign investments carry additional risks not generally associated with the domestic market. You should carefully consider whether any investment products or services mentioned herein are appropriate for you in view of your investment experience, objectives, financial resources and circumstances.
Hashtag: #PingAnDigitalBank #平安數字銀行
The issuer is solely responsible for the content of this announcement.
Ping An Digital Bank
Ping An Digital Bank (International) Limited (“Ping An Digital Bank,” “PingAnDB”) is a wholly-owned subsidiary of Lufax Holding Ltd (“Lufax”) (SEHK: 6623; NYSE: LU) and a member of Ping An Insurance (Group) Company of China, Ltd. (“Ping An”) (SEHK: 2318; SSE: 601318). Ping An Digital Bank was granted a banking licence by the Hong Kong Monetary Authority in May 2019 to offer retail banking and business banking services. Backed by Ping An’s advanced technology, Ping An Digital Bank is elevating banking experience, serving customer in Hong Kong and the Greater Bay Area, establishing itself as Ping An Group’s comprehensive financial platform in Hong Kong.
WRISE Prestige is the first firm in Hong Kong to offer the ChinaAMC Select Asia Bond Fund (Income Share Class), marking a milestone partnership that reinforces its standing as a leading wealth management firm.
The Fund’s Income share class * offers a target dividend yield of approximately 9%, combining strong historical performance with flexible, benchmark-unconstrained allocation to meet growing demand for income-generating solutions in Asia.
The partnership underscores WRISE’s commitment to expanding its curated suite of institutional-grade investment solutions for sophisticated investors across the region.
HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – WRISE Group (“WRISE“), one of Asia’s fastest-growing independent wealth management firm, announced that WRISE Prestige, has established a strategic partnership with China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)“), one of the region’s most established asset managers. Through this collaboration, WRISE Prestige will serve as the first launch partner in Hong Kong with a period of exclusive access to the ChinaAMC Select Asia Bond Fund (INC share class), offering clients a compelling fixed income solution designed for yield and diversification. To mark the partnership and the launch of the exclusive share class, WRISE Prestige and ChinaAMC (HK) co-hosted an event yesterday to formally announce the collaboration and introduce the investment strategy behind the ChinaAMC Select Asia Bond Fund to invited guests and clients.
The ChinaAMC Select Asia Bond Fund adopts a flexible, benchmark-unconstrained investment approach, allowing the fund manager to capitalise on opportunities across Asian credit markets dynamically. By focusing on fundamentally sound issuers, with a particular emphasis on China and the broader Asian region, the Fund seeks to deliver attractive risk-adjusted returns. Its strong historical track record underscoring the robustness of its investment process.
Recent geopolitical tensions have triggered significant volatility across global financial markets, making diversified, income-oriented strategies that can navigate geopolitical uncertainty paramount for sophisticated investors seeking portfolio resilience. With a target dividend yield of approximately 9%*, the Fund’s Income share class is positioned to address the increasing demand among Asian investors for stable and sufficient cash flow solutions. This income-focused strategy complements the broader portfolio needs of high-net-worth individuals seeking resilience and yield beyond traditional asset classes.
Henry Shin, Chief Executive Officer of WRISE Prestige, said: “We are delighted to partner with ChinaAMC to bring the ChinaAMC Select Asia Bond Fund (Income Share Class) to our clients as an exclusive launch in Hong Kong. In today’s volatile geopolitical landscape, investors require solutions that can adapt to changing conditions while delivering consistent income. The ChinaAMC Select Asia Bond Fund embodies this approach, offering flexible mandate and strong yield potential that make it a valuable addition to our curated platform.”
Barney Gao, Head of Strategic Client Development at China Asset Management (Hong Kong), said, “We are pleased to collaborate with WRISE Prestige to introduce the ChinaAMC Select Asia Bond Fund (Income Share Class) to investors in Hong Kong. This partnership reflects our commitment to delivering innovative and performance-driven investment solutions to a broader audience. With its focus on Asian bond markets and a flexible investment strategy, the Fund is well-suited to meet the income and diversification needs of investors in the region.”
This partnership highlights WRISE’s ongoing strategy to broaden access to best-in-class asset managers and deliver tailored investment solutions that address the complex and evolving needs of private wealth clients across Asia.
Important Information
This document is issued by WRISE Prestige Securities Limited (CE No. BSJ229). This document is for information purposes only and does not constitute and should not be construed as an offer, solicitation, recommendation or advice to buy or sell any investment product, nor should it be regarded as investment research.
Investment involves risks. The value of investments may go down as well as up and investors may not get back the principal invested. Past performance is not indicative of future performance.
The ChinaAMC Select Asia Bond Fund is authorized by the Securities and Futures Commission (“SFC”) in Hong Kong. SFC authorization is not a recommendation or endorsement of the Fund nor does it guarantee the commercial merits of the Fund or its performance. It does not mean the Fund is suitable for all investors.
Distributions (if any) are not guaranteed. Distribution rates are not indicative of the Fund’s return. The Fund may pay distributions out of income and/or capital (or effectively out of capital), which may result in an immediate reduction of the Fund’s net asset value.
This document has not been reviewed by the SFC.
* The Manager may at its discretion pay dividend out of capital or effectively out of the capital of the Funds. Payment of dividends out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any such capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Unit.
Hashtag: #WRISE
The issuer is solely responsible for the content of this announcement.
WRISE Group
WRISE is one of Asia’s fastest-growing financial firms, driven by strategic acquisitions of companies with deep expertise and solid foundations. With a strong presence across key financial hubs including Singapore, Dubai, Hong Kong, Shanghai, Shenzhen, Changsha, Taipei and Tokyo, WRISE is home to one of the largest networks of independent qualified advisors. With over 400 employees located globally, supported by an ecosystem of over 200 financial intermediaries and access to eight booking centres worldwide, WRISE ensures unparalleled service and expertise in navigating today’s financial landscape.
WRISE Group of companies include WRISE Wealth Management (Singapore), WRISE Wealth Management (Hong Kong), WRISE Wealth Management Middle East Ltd (DIFC, regulated by the DFSA), WRISE Prestige (Hong Kong) Limited, WRISE Prestige Securities (Hong Kong), WRISE Prestige Asset Management (Hong Kong), WRISE Capital (Hong Kong), WRISE Financial Services (Hong Kong) and affiliates including WeWrise Services.
China Asset Management (Hong Kong) Limited
Established in 2008, China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)”) is a leading Chinese asset manager in Hong Kong. The company is a wholly owned subsidiary of China Asset Management Co. Limited, one of the trusted asset managers and largest ETF provider in Mainland China with over USD 464.5 billion assets under management as of December 31, 2025.
ChinaAMC (HK) has amassed an impressive performance history in both active and passive investments over the past 17 years. Boasting robust expertise in a variety of asset classes, covering equities, fixed income, ETF, L&I products, digital assets, as well as mandates and investment advisory services. ChinaAMC (HK) adopts a global outlook to build a versatile platform catering to institutional and retail investors in the region and worldwide. All efforts align with their vision of being “Beyond China Expert”.
SINGAPORE – Media OutReach Newswire – 26 March 2026 – EarBalance Pte. Ltd., a well-established audiology clinic in Singapore, has unveiled a series of significant developments that underscore its commitment to redefining hearing and balance care. Formerly known as Sound Balance, the clinic has officially rebranded to EarBalance to better reflect its expanded scope of services and its collaborative approach with Ear, Nose and Throat (ENT) specialists. Alongside this transformation, the clinic is preparing to launch Singapore’s first FDA- and Health Sciences Authority (HSA)-approved over-the-counter (OTC) hearing aid solution, while also spearheading a major community hearing awareness initiative set to take place in June 2026.
Dr. Kenneth Chua, Senior Principal Audiologist, EarBalance Pte. Ltd.
These developments position EarBalance at the forefront of a shifting audiology landscape, one that increasingly prioritises accessibility, education, and holistic patient care.
A Strategic Rebrand to Reflect Broader Clinical Collaboration The transition from Sound Balance to EarBalance Pte. Ltd. marks more than a change in name. It signals a strategic evolution in the clinic’s identity and clinical philosophy. While the former name emphasised audiology and sound perception, the new brand encompasses a more comprehensive understanding of ear health, thus integrating both hearing and balance functions.
“Our ears are not just for hearing. Very often, we think about our five senses, which include hearing. The sixth sense, which is our balance, is often forgotten,” said Dr Kenneth Chua, Senior Principal Audiologist at EarBalance Pte. Ltd. Dr Chua also noted that the rebrand reflects the clinic’s commitment to addressing both aspects of ear health through a collaborative, multidisciplinary model that includes close partnerships with ENT specialists.
EarBalance has established strategic collaborations with several ENT groups, including ASCENT ENT Group, enabling a more seamless patient journey from diagnosis to treatment. This integrated care model ensures that patients presenting with hearing loss, dizziness, or vertigo receive comprehensive evaluation and management under one coordinated framework.
Introducing Singapore’s First FDA- and HSA-Approved OTC Hearing Aid In April 2026, EarBalance will launch the CERETONE OTC hearing aid, developed by a Canadian company in partnership with ENTRUST. This marks a significant milestone in Singapore’s hearing care sector, as it represents the first OTC hearing aid approved by both the U.S. Food and Drug Administration (FDA) and Singapore’s Health Sciences Authority (HSA).
Designed for individuals with mild hearing loss, CERETONE offers a cost-effective and accessible alternative to traditional prescription hearing aids. The device allows users to manage their hearing needs more independently, making it particularly suitable for those who may not yet be ready to commit to medical-grade solutions.
“This hearing aid is ideal for those with mild hearing loss and who may not be ready for medical-grade prescription hearing aids. We plan to continue expanding the inventory of innovative technological solutions to help people ‘hear better and live better,’” noted Dr Chua.
The CERETONE device combines a user-friendly design with specialised sound processing technology, enabling wearers to adjust settings according to their listening environment. This innovation aligns with EarBalance’s broader mission to “help people hear better and live better” by expanding its portfolio of technological solutions.
Addressing Industry Misconceptions Through Education EarBalance’s latest initiatives also reflect its stance on a persistent challenge within the hearing care industry: The perception of hearing aids as consumer commodities rather than medical interventions.
“The hearing industry has long been shaped by transactional relationships, where hearing aids are viewed as products to be sold,” added Dr Chua. “However, as healthcare professionals, our role is not to sell devices, but to guide patients in making informed decisions about their hearing health.”
This philosophy is particularly important in light of growing evidence linking untreated hearing loss to broader health risks. Studies have shown that up to 8 per cent of modifiable risk factors for dementia may be attributed to hearing loss. Early detection and intervention are therefore critical not only for communication but also for long-term cognitive health.
EarBalance places strong emphasis on patient education, ensuring that individuals understand the implications of hearing loss and the range of available interventions. By shifting the focus from sales to informed care, the clinic aims to foster trust and empower patients to take ownership of their hearing health.
Community Hearing Awareness Initiative to Launch in June 2026 In line with its commitment to public health, EarBalance will co-organise a large-scale community hearing awareness and education event in June 2026. The initiative is a collaboration between ASCENT ENT Group, EarBalance Audiology Clinic, and Thomson Medical Centre, with support from WS Audiology under the WSA (Wonderful Sound for All) foundation.
The event aims to address a critical gap in public awareness regarding hearing health, particularly the importance of early intervention. It will offer a comprehensive programme that includes hearing screenings, educational sessions, and professional consultations.
“Untreated hearing loss can lead to social isolation, reduced communication ability, and even cognitive decline,” Dr. Chua explained. “Through this initiative, we hope to encourage individuals to take proactive steps in managing their hearing health.”
The programme is expected to screen approximately 100 participants, with an estimated 40 to 50 individuals identified as needing hearing amplification support. For those facing financial barriers, refurbished hearing aids will be provided through CSR contributions, ensuring that care is accessible to underserved segments of the community.
A Holistic Approach to Hearing Rehabilitation Beyond screening and education, the June initiative will provide referral pathways for continued care, connecting participants with ENT specialists and audiologists for further evaluation and treatment. This integrated approach ensures that individuals identified with hearing loss receive not only a diagnosis but also actionable solutions.
The programme will also feature hearing health education sessions, designed to demystify common misconceptions and equip participants with practical knowledge about ear care. Topics will include the impact of hearing loss on overall well-being, the benefits of early intervention, and the range of available treatment options.
Media coverage and community engagement will play a key role in amplifying the initiative’s impact. WS Audiology, as a CSR partner, will be recognised through branding on programme materials, event displays, and media campaigns.
Sustainability Through Hearing Aid Upcycling EarBalance is also exploring sustainable practices within the hearing care space, particularly through the upcycling of hearing aids. Recognising that some patients may discontinue use of their devices, the clinic is considering programmes to refurbish and redistribute these aids to individuals in need.
“This initiative addresses two important issues, which are reducing electronic waste and improving access to hearing care,” said Dr Chua. “There are many individuals who could benefit from hearing aids but are unable to afford them. At the same time, there are devices that go unused. Bridging this gap is both a social and environmental responsibility.”
The proposed upcycling programme aligns with EarBalance’s broader vision of responsible healthcare, where innovation is balanced with sustainability and community impact.
Expanding the Scope of Ear Health: Hearing and Balance A defining feature of EarBalance’s clinical approach is its focus on both hearing and balance, which is an often-overlooked aspect of ear health. While hearing loss is widely recognised, balance disorders such as dizziness and vertigo are frequently misunderstood or underdiagnosed.
“Our ears are not just for hearing,” Dr Chua emphasised. “The vestibular system, located in the inner ear, plays a crucial role in maintaining balance. When this system is disrupted, patients may experience dizziness, vertigo, or instability, which can significantly affect their quality of life.”
EarBalance provides specialised assessment and rehabilitation for balance disorders, offering patients a comprehensive solution that addresses both auditory and vestibular health. This dual focus sets the clinic apart in Singapore’s audiology landscape, where balance care is often treated as a separate discipline.
Looking Ahead: Building a Future of Integrated Care As EarBalance continues to expand, it is exploring opportunities to further integrate hearing and balance services within clinical settings, including potential collaborations with Thomson Medical Centre. These efforts aim to create a seamless continuum of care for both adult and paediatric populations.
The clinic’s long-term vision includes the development of community-based programmes that extend beyond one-off initiatives, fostering sustained engagement and awareness around hearing health.
“Our goal is to build a healthcare ecosystem where hearing and balance care are accessible, integrated, and patient-centred,” said Dr Chua. “By combining clinical expertise, technological innovation, and community outreach, we hope to make a meaningful difference in people’s lives.” Hashtag: #EarBalance
The issuer is solely responsible for the content of this announcement.
About EarBalance Pte. Ltd.
EarBalance Pte. Ltd. is a Singapore-based audiology clinic dedicated to providing comprehensive hearing and balance care. Through a collaborative approach with ENT specialists and a focus on patient education, the clinic offers a range of services, including hearing assessments, hearing aid solutions, and balance rehabilitation. EarBalance is committed to helping individuals hear better and live better through accessible, innovative, and holistic care.
https://earbalancesg.com/
